Evaluation of the Efficacy and Safety of Drospirenone in the Treatment of Adenomyosis

Inclusion Criteria

• •age 18 years or older;
• •regular menstrual cycle;
• •adenomyosis diagnosed by imaging analysis (magnetic resonance imaging \[MRI\] or transvaginal ultrasound);
• •no other treatment for adenomyosis for at least 3 months before drospirenone administration;
• •painful symptoms (lower abdominal and/or lower back pain) with a score of three points or more on the verbal pain rating scale developed by Harada et al. during the menstrual cycle.